Cargando…
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here...
Autores principales: | Castagnoli, L, Ghedini, G C, Koschorke, A, Triulzi, T, Dugo, M, Gasparini, P, Casalini, P, Palladini, A, Iezzi, M, Lamolinara, A, Lollini, P L, Nanni, P, Chiodoni, C, Tagliabue, E, Pupa, S M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447867/ https://www.ncbi.nlm.nih.gov/pubmed/27641338 http://dx.doi.org/10.1038/onc.2016.338 |
Ejemplares similares
-
Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018) -
The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019) -
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017) -
HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness
por: Pupa, Serenella M., et al.
Publicado: (2021) -
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)